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Edited by Barry HalliwellAbstract Hypoxia regulates a variety of transcription factors
including HIF-1, which has been considered a target for anti-
angiogenic therapy. While searching for a novel anti-angiogenic
agent that would inhibit HIF-1 activity, we identiﬁed wondonin,
a new bis imidazole puriﬁed from an association of the sponges
Poecillastra wondoensis. Wondonin signiﬁcantly decreased hy-
poxia-induced HIF-1a protein and VEGF expression and inhib-
ited angiogenesis in vitro and in vivo. Furthermore, wondonin
down-regulated HIF-1a protein through the increased interac-
tion with the pVHL in immortalized human keratinocyte cell
line. Wondonin also decreased the immunoreactivities of CD31
and VEGF in epidermal hyperplasia in mice. Taken together,
these results suggested that wondonin had the potential to be-
come the anti-angiogenic therapeutic agent to target HIF-1a.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Angiogenesis, the formation of new blood vessels from pre-
existing endothelium, is a fundamental step in a variety of
physiological and pathological conditions including psoriasis,
wound healing, embryonic development, chronic inﬂamma-
tion, tumor progression, and metastasis [1–5]. The angiogenic
process is tightly controlled by a wide variety of positive or
negative regulators, such as growth factors, cytokines, lipid
metabolites, cryptic fragments of hemostatic proteins [6].
Among these molecules, VEGF, a soluble angiogenic factorAbbreviations: HIF-1, hypoxia-inducible factor-1; pVHL, von Hippel–
Lindau tumor suppressor protein; CAM assay, choriallantoic mem-
brane assay; HUVEC, human umbilical vein endothelial cells; HaCaT,
immortalized human keratinocyte cell line; VEGF, vascular endothe-
lial growth factor; TPA, 12-O-teterdecanoylphorbol-13-acetate
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doi:10.1016/j.febslet.2007.09.034produced by many tumor and normal cells, plays a key role
in regulating normal and abnormal angiogenesis [7]. Mean-
while, VEGF was also reported to be over-expressed in psori-
atic epidermis [8].
Hypoxia, a reduction in tissue oxygen levels, commonly
develops during several pathophysiological processes including
tumorigenesis [9]. Under hypoxia, cells are situated in unfavor-
able condition for cell growth whereas cancer cells may under-
go a series of genetic and metabolic changes that allow them to
survive and even proliferate with aberrant vasculature forma-
tion [9,10]. Forsythe et al. reported that the factors to regulate
hypoxic events may be good targets for anticancer therapy
because the cells surviving under hypoxic conditions often
become resistant to radiotherapy and chemotherapy [10,11].
One of such targets is a hypoxia-inducible factor-1 (HIF-1),
composed of heterodimer HIF-1a/HIF-1b subunits, which is
a key transcription factor regulating the blood supply. In addi-
tion, tumor growth and angiogenesis in xenograft tumors also
depend on HIF-1 activity and its expression level [12]. Recent
study by Kwon et al. also implicated the role of HIF-1a in
pathogenesis of psoriasis where angiogenesis is an essential
pathological feature [8].
A representative of new class of inorganic anti-tumor agents
is bisimidazole [13]. Recent progress in our understanding of
cellular and molecular biology led us to search for an anti-
angiogenic agent that would inhibit HIF-1 activity. Wondonin
is new agent belong to bis (dihydroxystyryl) imidazole group
of compounds derived from a close association of the sponges
[14]. In this study, we investigated the anti-angiogenic activity
of wondonin in vitro and in vivo to elucidate the underlying
molecular mechanisms. The following results from our exper-
iment suggest the potential application of wondonin as thera-
peutic agent for psoriasis and cancer.2. Materials and methods
2.1. Cell culture
Immortalized human keratinocyte cell line (HaCaT) were main-
tained in DMEM supplemented with 10% FBS, 100 U/ml of penicillin
and 100 lg/ml of streptomycin (Invitrogen). Human umbilical vein
endothelial cells (HUVECs) were maintained in M199 culture medium
(Invitrogen) with 20% FBS, 3 ng/ml bFGF (Upstate), and 5 U/ml
heparin (Sigma), and used between passages 3 and 6. All cells were
cultured in a humidiﬁed atmosphere containing 5% CO2 at 37 C.ublished by Elsevier B.V. All rights reserved.
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balanced N2 in hypoxic chamber (Forma Scientiﬁc).
2.2. Western blotting
Cells were lysed in a buﬀer (40 mM pH 7.4 Tris–HCl, 10 mM
EDTA, 120 mM NaCl, 0.1 % NP-40, 1 mM PMSF and protease inhib-
itor cocktail) on ice for 30 min. Cell lysates were centrifuged at
15000 · g for 30 min at 4 C and equivalent amounts of protein were
resolved by 6–12% SDS–PAGE. After electrophoresis, the proteins
were transferred onto nitrocellulose membrane (Amersham), which
were then blocked in blocking solution (5% skim milk in PBS contain-
ing 0.1% Tween 20) and incubated overnight at 4 C with antibodies
against HIF-1a (BD Pharmingen), VEGF (Santa Cruz), pVHL (BD
Pharmingen), a-tubulin (BioGenex) and b-actin (Sigma), followed by
reaction with a peroxidase-couple secondary antibody, which was then
detected with ECL-plus system (Amersham).
2.3. RNA isolation and RT-PCR analysis
RT-PCR was performed using total RNA isolated from the skin
biopsies by TRIzol reagent (Invitrogen, USA), according to the man-
ufacturer’s instruction and reverse-transcribed into cDNA, followed
by PCR using primer speciﬁc VEGF. GAPDH was used as internal
control cDNA ampliﬁcation. The sequences of primers used are:
(1) VEGF Forward: 5 0-GAGAATTCGGCCTCCGAAACCA-
TGAACTTTCTGT-30
Reverse: 5 0-GAGCATGCCCTCCTGCCCGGCTCACCGC-3 0
(2) HIF-1 alpha Forward: 5 0-AGTCGGACAGCCTCAC-3 0
Reverse: 5 0-TGCTGCCTTGTATAGGA-3 0
(3) GAPDH Forward: 5 0-ACCACAGTCCATGCCATCAC-3 0
Reverse: 5 0-TCCACCACCCTGTTGCTGTA-3 0
Detection of the mean band intensities (means ± S.D.) of PCR prod-
ucts were quantiﬁed following ethidium bromide staining (n = 3) using
densitometry (Bio-Rad Gel Doc 1000). Densitometry was measured as
the level of the densitometry of a speciﬁc band.
2.4. In vitro capillary tube formation assay with HUVECs on Matrigel
Matrigel (BD Pharmingen) was coated on 24-well culture plates and
polymerized for 30 min at 37 C. HUVECs (4 · 105 cells/24 well) were
seeded on Matrigel. Then, cells were incubated at 37 C. After 6 h,
morphologic changes of cells were observed and photographed
through a phase-contrast microscope [15].
2.5. Wounding migration assay
HUVECs, plated onto gelatin-coated culture dishes at 90% conﬂu-
ence, were wounded with a razor blade. After wounding, plates were
rinsed with serum-free medium to remove cellular debris. The
wounded monolayers were then incubated for 12 h in fresh medium
with 1 mM thymidine (Sigma). The cells were ﬁxed with absolute meth-
anol and stained with Giemsa’s solution (BDH Labotratory Supplies).
Migration was quantiﬁed by counting the number of cells that moved
beyond the reference line.
2.6. Invasion assay
Cell invasiveness was studied in modiﬁed Boyden chambers using
8 lm pored Transwell ﬁlter chambers (Corning-Costar). The upper
side of polycarbonate membranes was coated with Matrigel, and the
lower side of ﬁlter was coated with type IV collagen (BD Pharmingen).
HUVECs (3 · 104 cells/well) were placed in upper compartment of
Boyden chambers, and bovine serum albumin (Sigma) and bFGF were
treated in the lower chamber. The chambers were incubated at 37 C
for 16 h, the cells were ﬁxed with ice-cold methanol and stained with
hematoxyline/eosin (Sigma). Ability of cell invasion was determined
by counting the cell numbers at single ﬁlter.
2.7. CAM assay in chick embryo
Fertilized chicken eggs were incubated in a humidiﬁed egg breeder at
37 C. After incubation for 3 days, about 3 ml of egg albumin were re-
moved with an 18-gauze hypodermic needle, to allow the CAM and
yolk sac to drop away from the shell membrane. At the stage of 3-
day-old chick embryo, the shell was punched out and removed and
shell membrane was peeled away. At the stage of 4.5-day-old chick em-
bryo, a sample-loaded thermanox coverslips (NUNC) were air-dried
and applied to the CAM surface. Two days later, 1–2 ml of 10% fatemulsion was injected using a 33-gauze needle into a 6.5-day-old em-
bryo chorioallantois and observed under a microscope [16]. At least
20 eggs were used for each dose of sample.
2.8. Immunoprecipitation
Cell lysates in the lysis buﬀer (800 lg of protein) were incubated with
1 lg of antibodies at room temperature for 1 h in TEG buﬀer (20 mM
Tris–HCl pH 7.4, 1 mM EDTA, 10% glycerol, 1 mM dithiotheitol) and
then incubated with protein G-Sepharose beads (Upstate) at a dilution
of 1:50 for overnight at 4 C under rotation. Beads were washed ﬁve
times in supplemented TEG buﬀer (0.1% Triton X-100) and then sub-
jected to Western blotting.
2.9. TPA-induced hyperplasia in hairless mice skin
Seven week-old male albino hairless mice (SKH: HR-1) were ob-
tained from HanLim Lab. The animal facility was maintained at con-
stant temperature and humidity with a 12 h light-darkness cycle. Mice
were topically treated on the dorsal back with 200 ll acetone contain-
ing wondonin (50 mM) or the same volume of acetone alone 30 min
prior the application of 10 nmol 12-O-teterdecanoylphorbol-13-acetate
(TPA) in 200 ll acetone. The mice were treated twice topically with the
indicated doses of acetone or wondonin before TPA treatment at inter-
val of 24 h. The study was approved by the Institutional Animal Care
and Use Committee of Catholic University and all procedures were
conducted in accordance with the U.S. National Institutes of Health
guidelines.
2.10. Immunohistochemistry
The mice were sacriﬁced by the cervical dislocation 24 h after the
second treatment of acetone or wondonin. The tissue samples were re-
moved by 3 mm punch biopsy, ﬁxed overnight in 4% paraformalde-
hyde, and embedded in OCT compound (Tissue Tek). Sections of
4 lm were prepared and immunohistochemical staining was performed
using antibodies against endothelial cell marker, rat polyclonal anti-
CD31 (BD Pharmingen) and angiogenic factor rabbit polyclonal
anti-VEGF (Santa Cruz). Immunostaining was performed as previ-
ously described [17]. All images were acquired with a Carl Zeiss Axio-
skop2.
2.11. Statistical analysis
All data are expressed as means ± S.D. Student’s t-test was used to
establish which groups diﬀered from the control group. P < 0:05 was
considered statistically signiﬁcant.3. Results
The structure of wondonin is depicted in Fig. 1A. It was pre-
viously reported that wondonin inhibited the tube-formation
induced by basic ﬁbroblast growth factor (bFGF) at a concen-
tration of 10 lg/ml (about 10 lM) without showing any signif-
icant cytotoxicity toward the HUVEC [14].
3.1. Wondonin inhibits angiogenesis in vitro and in vivo
Hypoxia is the major stimulus for angiogenesis and HIF-1a
is its key mediator [18]. Loss of HIF-1a is known to inhibit a
number of important parameters of endothelial cell behavior
during angiogenesis and decrease level of VEGF expression
[18]. We therefore examine whether wondonin inﬂuences the
expression pattern of HIF-1a and VEGF. When HUVECs
were exposed to hypoxia for 16 h, the protein level of HIF-
1a and mRNA level of VEGF increased markedly. However,
wondonin suppressed HIF-1a protein and VEGF mRNA in
hypoxic endothelial cells (Fig. 1B).
To investigate whether wondonin aﬀect endothelial cell func-
tions relevant to angiogenesis, in vitro angiogenesis assays
were conducted under hypoxic conditions. HUVECs were pla-
ted onto Matrigel where they normally aligned and formed
Fig. 1. The structure of wondonin and its eﬀect of wondonin on the tube formation, migration, invasion in vitro, and embryo vasculogenesis. (A)
Chemical structure of wondonin. (B) HUVECs were incubated with 21% O2 or 1% O2 for 12 h with or without wondonin (10 lg/ml). HIF-1a protein
level was detected by Western blot analysis (top two panels). RT-PCR was performed using speciﬁc primer for VGEF and GAPDH (bottom two
panels). (C) HUVECs were incubated on polymerized Matrigel with or without wondonin (10 lg/ml) under normoxia or hypoxia for 16 h. The area
covered by the tube network was quantitated using Image-Pro Plus software. (D) Migration and (E) invasion of wondonin-treated HUVECs
compared with control under hypoxia for 16 h. (F) CAM surfaces were treated with vehicle (Con), RA (1 lg/egg) as a positive control, or wondonin,
respectively. The inhibition rate was a dose-dependency. Each bar represents mean ± S.D. (n = 3). *P < 0:05.
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ger and more robust with longer networks under hypoxia [18].
In contrast, wondonin profoundly inhibited hypoxia-stimu-
lated network formation of HUVECs, result in less elongated,
broken, and foreshortened tubes (Fig. 1C). Next, wounding
migration assay showed the movable ability of HUVECs was
enhanced under hypoxic conditions, whereas the migratory
ability of endothelial cells was reduced by wondonin
(Fig. 1D). The invasive activity was determined by counting
the number of the attached cells at the lower surface of mem-
brane. Compared with control cells, the invasive activity of
wondonin-treated cells into Matrigel was decreased to about
60% (Fig. 1E). Control CAMs showed well-developed zones
of neovascularization around and beneath the coverslip satu-rated with vehicle (DMSO). Retinoic acid (RA) is known to
antagonize angiogenesis and was used as a positive control.
Wondonin signiﬁcantly inhibited the formation of blood vessel
in a dose-dependent manner (Fig. 1F). The vessels formed
prior to vasculogenesis during embryonic development were
not aﬀected, but newly synthesized vessels sprouted from
pre-existing ones were markedly inhibited. These data demon-
strate that wondinin down regulated HIF-1a and VEGF,
resulting in reduced migration, invasion and tubular formation
of endothelial cells, and inhibited angiogenesis.
3.2. Eﬀect of wondonin on HIF-1a protein levels of HaCaT
The cell viability of HaCaT was analyzed by using MTT as-
say. The HaCaT were exposed to pre-determined concentra-
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when the HaCaT were treated with wondonin at diﬀerent con-
centrations (1–10 lg/ml) for 24 h, there was no signiﬁcant dif-
ference in cell viability compared with untreated controls. To
investigate whether wondonin can regulate hypoxia-induced
responses, we examined the protein level of HIF-1a in HaCaT
treated with wondonin for 16 h under hypoxia. As shown in
Fig. 2B, the expression of hypoxia-induced HIF-1a was signif-
icantly reduced in a dose-dependent manner. Although
wondonin down-regulated the level of hypoxia-induced HIF-
1a protein, it did not aﬀect its mRNA expression. These data
suggest that wondonin reduces the stability of HIF-1a protein.
Furthermore, to study whether the reduction of HIF-1a pro-
tein related with inhibition of hypoxia-induced angiogenesis,
we examined the expression of VEGF protein and mRNA
by treatment with wondonin under hypoxia. Fig. 2C showed
the wondonin gradually down-regulated the expression of hy-HIF-1
-tubulin
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Fig. 2. MTT assay and wondonin reduces HIF-1a protein levels. (A)
HaCaT were treated with wondonin at indicated concentration and
subjected to MTT assay. B and C, HaCaT were incubated with or
without wondonin under 21% O2 or 1% O2 for 16 h. HIF-1a protein
(B) and VEGF protein (C) were detected by Western blot analysis (top
two panels). RT-PCR was performed using speciﬁc primer for HIF-1a
(B) and VEGF (C) (bottom two panels). a-Tubulin and GAPDH
served as loading control.
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Fig. 3. Eﬀect of wondonin on the association between HIF-1a and
pVHL. (A) HaCaT were incubated with MG132 (10 lM) and/or
wondonin (10 lg/ml) under 1% O2 for 16 h. Anti-VHL immunopre-
cipitates (top two panels), anti-HIF-1a (middle two panels) and whole
cell lysates (bottom two panels) were analyzed by Western blot with
HIF-1a antibody and pVHL antibody. (B) HaCaT were incubated
with MG132 and/or wondonin for 16 h. Anti-HIF-1a immunoprecip-
itates (IP) were analyzed by Western blot with ubiquitin antibody.poxia-induced VEGF protein and mRNA in a dose-dependent
manner. These result that the down-regulation of VEGF by
wondonin may be due to the inhibition of HIF-1a activity.
Because the level of HIF-1a protein was dramatically de-
creased by wondonin, we examined the eﬀect of wondonin
on HIF-1a protein stability. von Hippel–Lindau tumor sup-
pressor protein (pVHL) is already known as a critical negative
regulator of HIF-1a stability depending on oxygen concentra-
tion [19–21]. To investigate whether HIF-1a degradation is due
to direct interaction with the pVHL, coimmunoprecipitaion
assays were conducted. After MG132 treatment, a speciﬁc
inhibitor of 26S proteasome, more HIF-1a/pVHL complexes
were detected in wondonin-treated cells than untreated con-
trols (Fig. 3A). Furthermore, to conﬁrm HIF-1a degradation
was due to the enhanced interaction between HIF-1a and
pVHL, we compared the ubiquitination pattern of HIF-1a
protein in the presence of MG132. As expected, the more
extensively ubiquitinated HIF-1a protein was observed in
wondonin treated cell than untreated controls (Fig. 3B). These
ﬁnding suggest that wondonin may inﬂuence the stability of
HIF-1a protein by accelerating its interaction with pVHL.
3.3. Eﬀect of wondonin on the expression of VEGF induced by
TPA treatment
Application of phorbol ester, such as TPA, was shown to in-
duce angiogenesis and epidermal hyperplasia as well as strong
inﬂammatory responses in SENCAR mice [22–25]. To investi-
gate if wondonin could alter the expression of CD31 and
VEGF in mice skin, we performed immunohistochemistry in
TPA-induced epidermal hyperplasia. TPA treatment, in the
Fig. 4. Immunohistochemistry of TPA-induced epidermal hyperplasia in the hairless mices. (A) Representative sections were stained by hematoxylin
and eosin staining in each group. White vertical bars indicate epidermal thickness of each group as shown 32 lm, 56 lm and 36 lm, respectively.
Yellow arrowheads indicate well-developed microvessels containing red blood cells. Scale bar: 115 lm. (B) Representative sections were processed for
immunohistochemical staining with anti-CD31 for endothelial cell marker in the dermis. White arrowheads indicate CD31-positive cells. Scale bar:
50 lm. (C) Representative sections were processed for immunohistochemical staining with anti-VEGF. Red arrowheads indicate VEGF-positive
cells. Scale bar: 60 lm.
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developed microvessels containing red blood cells [23].
Wondonin treatment, however, abolished TPA-induced epi-
dermal hyperplasia and microvessel development, yielding sim-
ilar image to that from control which was treated with acetone
(vehicle) alone (Fig. 4A).
To determine whether the inhibitory eﬀect of wondonin on
epidermal hyperplasia is associated with the suppression of
angiogenesis, we investigated the immunoreactivity of the
endothelial cell marker CD31. Only a few CD31+ vessels were
revealed in TPA-induced epidermal hyperplasia from wondo-
nin-treated mice, whereas signiﬁcantly more microvessels were
observed in the absence of wondonin (Fig. 4B). Finally, the
immunoreactivity of VEGF in microvessels of hyperplasia
was also decreased in the presence of wondonin (Fig. 4C). Ta-
ken together, the results presented here demonstrate that
wondonin can negatively regulate TPA-induced angiogenesis
and epidermal hyperplasia in mice, implying its potential ther-
apeutic utility.4. Discussion
Recent studies indicate that many common tumor-speciﬁc ge-
netic alterations also led to increased HIF-1a expression and/or
activity [26]. Although HIF-1 activity depends on the level of
available HIF-1a inside the cells, making this component good
anti-angiogenic target, only a few anti-tumor agent targeting
HIF-1a has been reported [27,28]. Here we show that wondo-
nin, a new bis (dihydroxylstyryl) imidazole, has the potential
to become a novel anti-angiogenic agent to target HIF-1a.
HIF-1 regulates the transcription of genes whose products
are involved in erythropoiesis, angiogenesis, glucose metabo-
lism, cell diﬀerentiation and migration, cell proliferation and
viability, vascular remodeling, vasomotor responses, CO2
metabolism, and ATP production [26]. Expression of the O2-
regulated HIF-1a subunit and HIF-1 transcriptional activity
are increased dramatically in hypoxic cells.
Wondonin reduced expression of HIF-1a and VEGF in
endothelial cells and could suppress HIF-dependent transcrip-
4982 H.-O. Jun et al. / FEBS Letters 581 (2007) 4977–4982tion in HaCaT. A crucial lead in understanding how HIF-1a
proteolysis is regulated by oxygen was the demonstration that
cells lacking pVHL have a high and stable level of HIF-1a pro-
tein(s) under standard oxygenation. It is of interest to note that
wondonin could increase the binding of pVHL to HIF-1a pro-
tein. Under normal physiological conditions, pVHL physically
binds to oxygen dependent-degradation (ODD) domain within
HIF-1a and mediates its degradation via ubiquitin-proteasome
pathway [29]. Thus, we anticipate that wondonin may enhance
the assembly of pVHL and HIF-1a to promote degradation of
HIF-1a.
The potential clinical application of wondonin was tested in
TPA-induced epidermal hyperplasia in hairless mice [23]. The
cells in hyperplasia and tumors become hypoxic because they
are too distinct from nearby vessels and respond to hypoxia-in-
duced angiogenic factors [3,30–33]. In animal models, we
found that wondonin also decreased the immunoreactivities
of CD31 and VEGF in TPA-induced epidermal hyperplasia.
Taken together, the potential of wondonin as a novel anti-
angiogenic agent was investigated. The results from both
in vitro and in vivo experiments demonstrated that wondonin
plays a role in HIF-1a stability negatively and leads to the
decrease of VEGF expression, and ﬁnally enhances the
anti-angiogenic activity, suggesting its clinical application in
anti-angiogenesis, including psoriasis and cancer.
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